Overview

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Status:
NOT_YET_RECRUITING

Trial end date:
2028-05-31

Target enrollment:

Participant gender:

Summary

This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai JMT-Bio Inc.

Treatments:

Zoledronic Acid